Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 4;23(17):10120.
doi: 10.3390/ijms231710120.

EVOO's Effects on Incretin Production: Is There a Rationale for a Combination in T2DM Therapy?

Simona Amodeo  1 , Luigi Mirarchi  1 , Aurelio Seidita  1 , Roberto Citarrella  1 , Anna Licata  1 , Maurizio Soresi  1 , Juan Lucio Iovanna  2 , Lydia Giannitrapani  1   3
Affiliations
Review

EVOO's Effects on Incretin Production: Is There a Rationale for a Combination in T2DM Therapy?

Simona Amodeo et al. Int J Mol Sci. .

Abstract

Type 2 diabetes mellitus (T2DM) is a serious public health concern as it is one of the most common chronic diseases worldwide due to social and economic developments that have led to unhealthy lifestyles, with a considerable impact both in terms of morbidity and mortality. The management of T2DM, before starting specific therapies, includes cornerstones such as healthy eating, regular exercise and weight loss. Strict adherence to the Mediterranean diet (MedDiet) has been related to an inverse association with the risk of T2DM onset, as well as an improvement in glycaemic control; in particular, thanks to the consumption of extra virgin olive oil (EVOO). Agonists of gut-derived glucagon-like peptide-1 (GLP-1), gastrointestinal hormones able to increase insulin secretion in response to hyperglycaemia (incretins), have been recently introduced in T2DM therapy, quickly entering the international guidelines. Recent studies have linked the action of EVOO in reducing postprandial glycaemia to the increase in GLP-1 and the reduction of its inactivating protease, dipeptidyl peptidase-4 (DPP-4). In this review, we explore observations regarding the pathophysiological basis of the existence of an enhanced effect between the action of EVOO and incretins and, consequently, try to understand whether there is a rationale for their use in combination for T2DM therapy.

Keywords: EVOO; GLP-1; MedDiet; T2DM.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
EVOO and GLP-1 RA actions on gastric and pancreatic functions and their possible synergistic effects on glycaemic control and cardiovascular risk. The green arrows symbolize EVOO actions, the light blue, GLP-1 RA actions.
See this image and copyright information in PMC

References

    1. International Diabetes Federation . IDF Diabetes Atlas. 10th ed. Brussels, Belgium: 2021. [(accessed on 1 July 2022)]. Available online: https://www.diabetesatlas.org.
    1. Marrano N., Biondi G., Cignarelli A., Perrini S., Laviola L., Giorgino F., Natalicchio A. Functional loss of pancreatic islets in type 2 diabetes: How can we halt it? Metabolism. 2020;110:154304. doi: 10.1016/j.metabol.2020.154304. - DOI - PubMed
    1. Shah A.D., Langenberg C., Rapsomaniki E., Denaxas S., Pujades-Rodriguez M., Gale C.P., Deanfield J., Smeeth L., Timmis A., Hemingway H. Type 2 diabetes and incidence of cardiovascular diseases: A cohort study in 1.9 million people. Lancet Diabetes Endocrinol. 2015;3:105–113. - PMC - PubMed
    1. Gregg E.W., Li Y., Wang J., Rios Burrows N., Ali M.K., Rolka D., Williams D.E., Geiss L. Changes in diabetes-related complications in the United States, 1990–2010. N. Engl. J. Med. 2014;370:1514–1523. - PubMed
    1. Rawshani A., Rawshani A., Franzén S., Eliasson B., Svensson A.-M., Miftaraj M., McGuire D.K., Sattar N., Rosengren A., Gudbjörnsdottir S. Mortality and cardiovascular disease in Type 1 and Type 2 diabetes. N. Engl. J. Med. 2017;376:1407–1418. - PubMed

MeSH terms